Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer
Authors:
Open Access
- 22 May 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-12
Abstract
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer characterized by metastasis, drug resistance and high rates of recurrence. With a lack or targeted therapies, TNBC is challenging to treat and carries a poor prognosis. Patients with TNBC tumors expressing high levels of ERK2 have a poorer prognosis than those with low ERK2-expressing tumors. The MAPK pathway is often found to be highly activated in TNBC, however the precise functions of the ERK isoforms (ERK1 and ERK2) in cancer progression have not been well defined. We hypothesized that ERK2, but not ERK1, promotes the cancer stem cell (CSC) phenotype and metastasis in TNBC. Stable knockdown clones of the ERK1 and ERK2 isoforms were generated in SUM149 and BT549 TNBC cells using shRNA lentiviral vectors. ERK2 knockdown significantly inhibited anchorage-independent colony formation and mammosphere formation, indicating compromised self-renewal capacity. This effect correlated with a reduction in migration and invasion. SCID-beige mice injected via the tail vein with ERK clones were employed to determine metastatic potential. SUM149 shERK2 cells had a significantly lower lung metastatic burden than control mice or mice injected with SUM149 shERK1 cells. The Affymetrix HGU133plus2 microarray platform was employed to identify gene expression changes in ERK isoform knockdown clones. Comparison of gene expression levels between SUM149 cells with ERK2 or ERK1 knockdown revealed differential and in some cases opposite effects on mRNA expression levels. Those changes associated with ERK2 knockdown predominantly altered regulation of CSCs and metastasis. Our findings indicate that ERK2 promotes metastasis and the CSC phenotype in TNBC.Keywords
This publication has 44 references indexed in Scilit:
- Identification of Biological Targets of Therapeutic Intervention for Hepatocellular Carcinoma by Integrated Bioinformatical AnalysisMedical Science Monitor, 2018
- REC8 inhibits EMT by downregulating EGR1 in gastric cancer cellsOncology Reports, 2018
- A novel EGR‐1 dependent mechanism for YB‐1 modulation of paclitaxel response in a triple negative breast cancer cell lineInternational Journal of Cancer, 2016
- ERK2 Alone Drives Inflammatory Pain But Cooperates with ERK1 in Sensory Neuron SurvivalJournal of Neuroscience, 2015
- The MAPK pathway across different malignancies: A new perspectiveCancer, 2014
- Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasisBritish Journal of Cancer, 2014
- ERK-ERF-EGR1, a novel switch underlying acquisition of a motile phenotypeCell Adhesion & Migration, 2013
- Early growth response 1 regulates glucose deprivation-induced necrosisOncology Reports, 2012
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets, 2012
- Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression.2002